Investors in two major Chinese companies have recently taken further legal action.
On June 1, 2026, a new batch of investor compensation claims against Wuliangye Yibin Co.,Ltd. (SHE: 000858) were submitted for filing at the Chengdu-Chongqing Financial Court by lawyer Xu Feng from Shanghai Jiucheng Law Firm.
This follows an earlier batch of claims for the same company that were officially accepted by the court on May 20, 2026, and are now awaiting further court proceedings. The legal team continues to handle subsequent cases and is accepting new mandates from other affected investors.
The legal action is connected to an accounting error correction announced by Wuliangye on the evening of April 30, 2026. The company stated that its board and audit committee had reviewed and passed a resolution concerning the correction of prior-period accounting errors, with details disclosed in accordance with relevant accounting and disclosure regulations.
Legal counsel suggests that investors who purchased Wuliangye shares between April 28, 2025, and May 1, 2026, and sold or continued holding them after May 1, 2026, may currently be eligible to file claims, subject to final court determination.
Initiating Legal Proceedings
Separately, on the same date of June 1, 2026, a new set of investor claims against Dr.Peng Telecom&Media Group Co.,Ltd. (SHA: 600804) was also submitted for court filing by lawyer Xu Feng. The case is entering the final countdown period of its litigation时效, prompting a reminder for investors to act.
In late January 2026, one Dr.Peng investor represented by the lawyer received compensation through mediation. However, claims for other investors have proceeded to court for enforcement, as the company and its chairman, Yang Xueping, failed to fulfill payment obligations as per the mediation agreement.
There is already a precedent of a favorable court judgment for Dr.Peng investors. The legal team is actively progressing with filing subsequent cases and continues to accept new mandates.
The claims stem from a penalty decision issued by the China Securities Regulatory Commission on August 16, 2024. The regulator found Dr.Peng guilty of several violations, including failure to disclose关联交易 and重大合同 as required, and falsifying records in its annual reports from 2012 to 2022.
The specifics involved overstating profits and assets in various years. For instance, profits were inflated by approximately 42.5 million yuan in 2012, representing 17.43% of that year's total profit. From 2020 to 2022, each annual report understated net assets by 196 million yuan.
Based on the previous successful judgment, legal counsel indicates that investors who purchased Dr.Peng shares between April 12, 2013, and July 18, 2023, and sold or held them after July 18, 2023, may currently be eligible to seek compensation.
Comments